Covaxin efficacy data has no effect on opposition states
SECTIONS
Share
Synopsis
A day after Hyderabad-based Bharat Biotech reported its interim data, the three states on Thursday said they would wait for a formal approval from the Drugs Controller General of India (DCGI) before using Covaxin for the immunisation drive.
AFP
The Opposition-ruled states of Punjab, Chhattisgarh and Kerala, which have refused to use Bharat Biotech s Covaxin, have not changed their stance even after the manufacturer released interim data showing 81% vaccine efficacy in phase 3 clinical trial.
A day after Hyderabad-based Bharat Biotech reported its interim data, the three states on Thursday said they would wait for a formal approval from the Drugs Controller General of India (DCGI) before using Covaxin for the immunisation drive.
With Nearly 14 Lakh Vaccines In 24 Hours, India Sets A New Record In The Fight Against COVID-19 indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Covaxin Demonstrates Interim Clinical Efficacy Of 81 Per Cent In Phase 3 Trial: Bharat Biotech
by Swarajya Staff - Mar 4, 2021 03:19 AM
Bharat Biotechâs COVAXIN, Indiaâs first indigenous vaccine against coronavirus. (Swarajya Magazine)
In a positive development for India s fight against the Covid-19 pandemic, Hyderabad-based Bharat Biotech on Wednesday (3 March) announced the first interim analysis of India s first Covid-19 vaccine candidate Covaxin, which, the company said, demonstrated an interim efficacy of nearly 81 per cent in phase 3 clinical trials.
The clinical trials, which were conducted in partnership with Indian Council of Medical Research (ICMR), involved 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities, the company said.
As India s Vaccine Drive Expands, Here s What We Know About the Two Available Shots thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewire.in Daily Mail and Mail on Sunday newspapers.